Al Hammadi Holding · TADAWUL:4007
Al Hammadi — Investor Presentation (2023)
20 slides from Al Hammadi's investor presentation, 2023
Slide 1: Investor Presentation FY 2023
Al Hammadi Holding Investor Presentation FY 2023
Slide 2: Table of Contents
Table of Contents I II III About Al Hammadi Holding FY 2023 Appendix Results Overview
Slide 3: About Al Hammadi Holding
About Al Hammadi Holding
Slide 4: An Integrated Healthcare Company
Al Hammadi is an integrated healthcare company and premier hospital operator providing world-class healthcare services to hundreds of thousands of local and foreign residents… An Integrated Healthcare Company 81%1 19%1 The company currently operates two hospitals in the Saudi Arabian capital, housin
Slide 5: Riyadh coverage and hospital locations
The Company enjoys widespread coverage spanning the entire Saudi capital Al Narjis Hospital2 4 Al Nuzha Hospital 3 Al Hammadi boasts two operational state-of-the-art facilities, Al Nuzha and Al Suwaidi hospitals, strategically located in the heart Riyadh Olaya Hospital1 of Riyadh, with a third hospi
Slide 6: Two premier hospitals in the heart of Riyadh
Al Hammadi operates two premier hospitals in the heart of Riyadh providing a wide range of world-class services to thousands of patients Patient Class Mix Patient Class Mix Al Nuzha Hospital 2023 Al Suwaidi Hospital 2023 Located in the northeast neighborhood of Launched in 2015 and located in southw
Slide 7: Growth plans to add rooms and clinics by 2028
The Group’s ambitious growth plans will see it add 400 rooms and 240 clinics by 2028 to capitalize on the city’s growing healthcare demand Al Suwaidi Hospital Olaya Hospital Al Narjis Hospital Al Hammadi is looking to Originally launched in 1985, The Group plans to open its leverage Al Suwaidi’s spa
Slide 8: FY 2023 Results Overview
FY 2023 Results Overview
Slide 9: FY 2023 Results Snapshot
FY 2023 Results Snapshot Al Hammadi delivered strong financial results throughout 2023 driven by solid revenue growth and efficient cost management strategies Revenue Gross Profit Operating Profit Net Profit SAR 1,177 Million SAR 433 Million SAR 347 Million SAR 303 Million FY 2023 (▲4.8% y-o-y) FY 2
Slide 10: FY 2023 Operational Review
FY 2023 Operational Review Inpatient volumes declined in 2023 compared to last year and outpatient examination decrease marginally versus the comparable period of 2022 Inpatient Admissions | ‘000 Outpatient Examinations| ‘000 ▼ 1% ▼10% 45.0 1,038.6 1030.7 40.2 40.6 974.1 33.3 812.9 FY2020 FY2021 FY2
Slide 11: Consolidated Financial Performance (I/III)
FY 2023 Consolidated Financial Performance (I/III) Revenue growth for the year was fueled by strong revenues across Al Hammadi’s medical services and in-house pharmacies Revenues maintain growth trend, with increasing inpatient and outpatient revenues Average Revenue per Inpatient Revenues | SAR Mn
Slide 12: Consolidated Financial Performance (II/III)
FY 2023 Consolidated Financial Performance (II/III) Bottom-line profitability came on the back of robust top-line growth coupled with a significant decrease in costs at the SG&A level and a notable 65% y-o-y reduction in expected credit loss provisions Cost management successfully reduced general an
Slide 13: Consolidated Financial Performance (III/III)
FY 2023 Consolidated Financial Performance (III/III) Robust revenues filtered down to the net profit level, which grew 18% y-o-y in 2023 Net Profit before Zakat | SAR Mn Net Profit | SAR Mn 25.8% 400 27.3% 24.4% 3 0 .0% 22.9% ▲ 17.1% 350 15.2% 11.4% ▲ 17.9% 2 0 .0% 300 13.0% 1 0 .0% 9.5% 250 0 .0 %
Slide 14: Al Nuzha Hospital: FY 2023 Performance
Al Nuzha Hospital: FY 2023 Performance Continued top-line growth reported despite lower patient volumes in 2023 as the company admitted a higher volume of complex cases throughout the year Patient volumes slightly affected due to the reclassification of Al Hammadi’s facilities with insurance compani
Slide 15: Al Suwaidi Hospital: FY 2023 Performance
Al Suwaidi Hospital: FY 2023 Performance Al- Suwaidi’s top-line grew despite lower volumes in 2023 Patient volumes slightly down due to the reclassification of Al Hammadi’s facilities with insurance companies Outpatient Examinations | ‘000 Inpatient Admissions | ‘000 5.8% CAGR 6.9% CAGR 18.9 396.0 3
Slide 16: Pharmaceuticals: FY 2023 Performance Review
Pharmaceuticals: FY 2023 Performance Review Al Hammadi’s pharmaceutical sales contributed 19% of consolidated revenues, recording SAR 226 million for in 2023 Revenue from In-House Pharmacies| SAR Mn Revenue from Pharma Serve| SAR Mn 250 200 180 ▲10.4% 200 160 140 150 120 100 187 100 199 80 180 161 1
Slide 17: Appendix
Appendix
Slide 18: Consolidated Income Statement
FY 2023 Consolidated Income Statement SAR mn Q4 2022 Q4 2023 Y-o-Y Change FY 2022 FY 2023 Y-o-Y Change Revenue 342.6 303.7 -11.4% 1,122.4 1,176.8 4.8% Cost of revenue (214.6) (197.2) -8.1% (702.7) (743.6) 5.8% Gross Profit 128.0 106.4 -16.8% 419.7 433.1 3.2% GPM 37.4% 35.1% 2.3pts 37.4% 36.8% -0.6pt
Slide 19: Consolidated Balance Sheet
FY 2023 Consolidated Balance Sheet SAR mn 31 December 2022 31 December 2023 ASSETS Non-current assets Property and equipment 1,606.2 1,658.6 Advance payments for acquisition of property and equipment 95.8 - Intangible assets and goodwill 28.5 23.7 Investment in associates 124.2 128.4 Total non-curre
Slide 20: Consolidated Statement of Cash Flow
FY 2023 Consolidated Statement of Cash Flow SAR mn 31 December 2022 31 December 2023 OPERATING ACTIVITIES Net profit 257.3 303.3 Adjustments to reconcile net profit to cash flow - - Depreciation of property and equipment and right of use assets 96.7 97.0 Amortization of intangible assets 3.7 3.1 Los